Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biohaven Pharmaceutical Holding Co. Ltd.

www.biohavenpharma.com

Latest From Biohaven Pharmaceutical Holding Co. Ltd.

Troriluzole Fails First Phase III Test As Biohaven Looks Beyond Migraine

Biohaven is still studying its glutamate modulator in three other indications, but its biggest near-term milestone will be approval of the oral CGRP inhibitor rimegepant for acute migraine.

Clinical Trials Neurology

Finance Watch: Billions Of Dollars In Offerings Despite US Biopharma Stock Slump

Blueprint and Zymeworks raise $300m-plus in follow-on offerings. Also, Arcutis, Black Diamond and Annovis bring the 2020 US IPO count to four; Spring Bank, Surface Oncology and Decibel reveal strategic shifts; and Harmony’s $200m in venture debt leads recent VC deals.

Financing Innovation

Lilly, Allergan Beat Biohaven To Acute Migraine Market With Reyvow, Ubrelvy Launches

After DEA scheduling, Reyvow will be available at pharmacies soon with a list price of $640 for eight tablets. Allergan confirmed that its drug is at pharmacies and prescriptions are being filled.

Launches Neurology

Market Snapshot: Three Acute Migraine Launches Are First In Over 20 Years

Lilly, Allergan and Biohaven plan to launch oral drugs for on-demand treatment of migraine attacks in the first quarter, hoping to harness a large market where new preventive therapies are already competing for patients.

Launches Market Intelligence
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Biohaven Pharmaceuticals
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Biohaven Pharmaceutical Holding Co. Ltd.
  • Senior Management
  • Vlad Coric, MD, CEO
    Jim Engelhart, CFO
    Robert Berman, MD, CMO
    John Tilton, Chief Commercial Officer
    Charlie Conway, PhD, CSO
    Elyse Stock, MD, Chief, Portfolio Strategy & Dev.
    Donnie McGrath, MD, Chief, Corp. Strategy & Bus. Dev.
    Kim Gentile, VP, Operations
  • Contact Info
  • Biohaven Pharmaceutical Holding Co. Ltd.
    Phone: (203) 404-0410
    234 Church St.
    New Haven, CT 06510
    USA
UsernamePublicRestriction

Register